Novartis sanctioned in Belgium for undermining rival drug

The Belgian Competition Authority has fined Novartis €2.8 million after concluding it unlawfully shut out competition in the market for certain eye disease treatments by exaggerating the potential side effects of a rival drug.

Unlock unlimited access to all Global Competition Review content